Moderna’s COVID Vaccine Gains Full FDA Approval for Children Aged 6 Months and Older
TL;DR Summary
The FDA has granted full approval for Moderna's COVID-19 vaccine, Spikevax, for children aged 6 months to 11 years at increased risk, expanding beyond emergency use authorization, with availability expected for the 2025-26 season.
- Moderna gets full US approval for COVID shot in at-risk children 6 months and older Reuters
- FDA grants full approval to Moderna’s Covid vaccine for children but limits eligibility STAT
- Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease Yahoo Finance
- Moderna’s Covid Shot Fully Approved by FDA for Use in Children Bloomberg
- Moderna stock rating reiterated at Buy by Brookline Capital Markets Investing.com
Reading Insights
Total Reads
1
Unique Readers
1
Time Saved
2 min
vs 2 min read
Condensed
91%
370 → 34 words
Want the full story? Read the original article
Read on Reuters